ArticleViruses2026
miR-26a-5p Activates Antiviral Innate Immunity via Direct Binding and Activation of RIG-I.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Emerging evidence has revealed the critical roles of microRNAs (miRNAs) in the regulation of innate immune responses. Nevertheless, it remains poorly understood whether specific miRNAs can directly modulate retinoic acid-inducible gene I (RIG-I), a principal sensor of cytoplasmic viral RNA and a key initiator of antiviral innate immunity. In this study, we identified miR-26a-5p as a potent activator of the innate antiviral immune responses. Notably, this activation operates independently of the canonical miRNA pathways of translational repression and mRNA degradation. Instead, we demonstrated that miR-26a-5p exerts its immunostimulatory effects by specifically binding to the RIG-I receptor. RNA immunoprecipitation and RNA pull-down assays confirmed a direct physical interaction between miR-26a-5p and the RIG-I protein. Subsequent site-directed mutagenesis verified that an AU-rich motif is critical for miR-26a-5p-driven RIG-I activation. Viral challenge experiments demonstrated that miR-26a-5p confers broad-spectrum, RIG-I-dependent antiviral activity against both DNA viruses (herpes simplex virus type 1 and Kaposi's sarcoma-associated herpesvirus) and RNA viruses (influenza A virus and respiratory syncytial virus). Collectively, our study indicates that miR-26a-5p may serve as a ligand that binds to and activates the RIG-I receptor. This discovery uncovers a previously unrecognized mechanism through which host miRNAs regulate antiviral innate immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.